Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance

NCT00582166 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

18

Enrollment

OTHER

Sponsor class

Stopped See 'Limitations and Caveats' section

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG: Ibritumomab Tiuxetan (Zevalin) + Rituximab

Sponsor

University of Wisconsin, Madison

Collaborators

[object Object]